Drug intelligence / Profile preview

pollenin B

Development stage: Preclinical
Modality: Small Molecules
Administration: Subcutaneous, Sublingual, Intradermal, Oral, Intranasal, Epicutaneous, Intralymphatic

Overview

Pollenin B (PolB) is a compound extracted from Ephedrae Herba, currently under investigation for its protective effects in asthma. It has demonstrated the ability to improve asthma symptoms, modulate cytokine levels, and influence immune cell populations and arachidonic acid metabolism in asthmatic mice. Its anti-asthmatic effects are primarily mediated through the regulation of inflammatory pathways and arachidonic acid metabolism, as well as the JAK-STAT pathway, via its interaction with PPAR-γ.

Targets

PPARG (Peroxisome proliferator-activated receptor gamma)

Beyond the preview

Go deeper on pollenin B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pollenin B.

Explore the full profile